The present study indicates that the Tirzepatide is a promising drug with dual acting glucose dependent insulin tropic polypeptide peptide and glucagon like peptide receptor activation that has revolutionized the treatment of type 2 diabetes mellitus. Tirzepatide is indicated to improve blood sugar control in adults with type 2diabetes as an additional to diet and exercise. It is also indicated as an adjunct to reduced calorie diet and increased physical activity for chronic weight management. Tirzepatide has demonstrated significant benefits in obese patients with a common type of heart failure, preserved ejection fraction in a phase 3 trail. Over two years,Tirzepatide reduced the risk of major complications including urgent heart failure visits, hospitalizations, increased diuretic treatment and cardiovascular related deaths by 38% compared to placebo.This makes Tirzepatide has been shown to achieve better glycemic control in terms of glycosylated hemoglobin reduction and improve fasting and post pride in a glucose levels as combined with other diabetic medications.Tirzepatide has acceptable side effects in this well tolerated with lower risk of hyperglycemia . In this review we have summarized the clinical trials and their respective outcomes in highlighted the potential future indications for tirzepatide in the management of obesity, heart failure, non alcoholic steatohepatitis. (1) Key Words: Tirzepatide, type 2 diabetes mellitus, chronic weight management, benefits in obese patients with a common type of heart failure, preserved ejection fraction in a phase 3 trail.